Moderna COVID-19 vaccine ‘promises’ an immune response and safety at Stage 1 research

The experimental vaccine against COVID-19, which is being developed by the American company Moderna, was able to elicit an immune response in all volunteers at an early stage of the study. Relevant data is published in the New England Journal of Medicine.

The study showed that some antibodies were produced after a single dose of the vaccine, however, four weeks later a second dose was required, after which the vaccine elicited a strong immune response in all 45 volunteers.

According to Moderna CEO Stephane Bancel, the results are “encouraging and represent an important step forward in the clinical development of mRNA-1273, our candidate for the COVID-19 vaccine.”

The study involved 45 healthy volunteers between the ages of 18 and 55 at Seattle and Emory University in Georgia. Participants in the experiment were given three dose levels of the Moderna vaccine at 25, 100, and 250 micrograms.

On July 27, Moderna is expected to begin a much larger study of the third-stage vaccine trial, which will bring together 30,000 participants in 87 locations.

 

If you have found a spelling error, please, notify us by selecting that text and pressing Ctrl+Enter.

Leave a Comment

This site uses Akismet to reduce spam. Learn how your comment data is processed.

Author: Sam Smith
Graduated from University of Oxford. Previously, he worked in various diferent news media. Currently, it is a columnist of the world news section in the Free News editors.
Function: Editor
Sam Smith

Spelling error report

The following text will be sent to our editors:

36 number 0.253710 time